AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01741402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training
Description: The participants of the study trained 10 balance games during 14 sessions
Study NCT01741402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Patients of the control group was trained with balance exercises.
Study NCT03171753 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire
Description: questionnarie will be performed before the application of headphone and after their removal.
Study NCT03171753 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: questionnarie will be performed before the application of headphone and after their removal.
Study NCT01438697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Intervention
Description: Participants will spend 1-2 hours each week for 9 weeks using the Internet intervention. Users will complete daily sleep diaries as well as interactive tutorials covering the topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention. As users progress through the program they will receive tailored instructions for how to improve their sleep.
Study NCT03171753 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: laboratory test
Description: laboratory test will be collected before the application of headphone and after their removal. the cardiac monitoring will be performed during the all study period
Study NCT01438697 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education Website
Description: Participants will be given access to a relevant patient education website. It will contain material addressing the behaviors and symptoms of insomnia.
Study NCT03479047 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: assess diaphragmatic displacement (DD) using ultrasonography
Description: During a spontaneous breathing trial (SBT) we will simultaneously, for all included patient, assess diaphragmatic displacement (DD) using ultrasonography, respiratory rate (RR) and tidal volume (VT) on ventilator screen.
Study NCT02686294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL151
Description: Test drug : HL151. 1T, once a day oral administration, for 4 days
Study NCT03171753 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: laboratory test
Description: laboratory test will be collected before the application of headphone and after their removal. the cardiac monitoring will be performed during the all study period
Study NCT03171753 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cardiac monitoring
Description: the cardiac monitoring will be performed through study period
Study NCT03171753 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cardiac monitoring
Description: the cardiac monitoring will be performed through study period
Study NCT03171753 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: skin resistance
Description: the skin resistance monitoring will be performed through study period
Study NCT03171753 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: skin resistance
Description: the skin resistance monitoring will be performed through study period
Study NCT03171753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Music listening
Description: Listening prerecorded music through an individual headset for 30 min
Study NCT03171753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No sound
Description: No sound through an individual headset for 30 min
Study NCT03153384 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Culture
Description: For each patient, one single high volume blood culture (3 aerobic and 3 anaerobic of 8 to 10 mL each, numbered), and then 2 samples of 16 to 20 mL (one aerobic bottle and one anaerobic for each sample).
Study NCT01583829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: 3 times per week for 45 minutes for a total of 40 sessions
Study NCT01583829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: 3 times per week for 45 minutes for a total of 40 sessions
Study NCT01583829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: 6 30 minute calm breathing sessions over the course of 4 months
Study NCT04497883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir (400 mg)
Description: Non-Hispanic, Caucasian group and Japanese descent group participants will receive 400 mg maribavir tablets orally once on Day 1 during treatment period 1.
Study NCT04497883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir (200 mg)
Description: Japanese descent group participants will receive 200 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
Study NCT04497883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir (800 mg)
Description: Japanese descent group participants will receive 800 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
Study NCT02567058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound exam
Description: Ultrasound exam with :~* 2 successions of 3 measures repeated for 2 visits (day 0 and day 21) for group I~* 1 succession of 3 measures repeated for 4 visits (day 0, day 14, day 45, day 90)for group II~* 1 succession of 3 measures for group III
Study NCT02567058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPAQ questionnaire
Description: IPAQ questionnaire
Study NCT04924439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot reflexology
Description: Foot reflexology was applied to the experimental group for 40 minutes once a week for postpartum 8 weeks. The control group was only watched.
Study NCT01104532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral tablet
Study NCT01104532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: oral tablet
Study NCT02686294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALION tab.
Description: Reference drug : TALION tab. 1T, twice a day oral administration, for 4 days
Study NCT01384682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: Maraviroc is a marketed drug for the treatment of HIV-infection. Maraviroc will be supplied in two different oral dose forms, 150mg and 300mg given twice a day. The drug will be dosed according to the recommendations in the product label i.e. with PI/r the dose is 150mg bid except, Maraviroc 300mg bid can be used at the discretion of the investigator if the PI/r is fosamprenavir/r; those randomised to the 2N(t)RTI arm, will receive Maraviroc 300mg bid. Patients randomised to receive Maraviroc will be provided with bottles of Maraviroc which contain a 30-day supply.
Study NCT01872338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Cognitive Therapy for Suicide
Description: Psychotherapeutic intervention that integrates mindfulness meditation with Safety Planning, with a specific focus on reducing suicide risk.
Study NCT01872338 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: VA standard care for suicide prevention
Study NCT04067518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHP674
Description: SHP674: powder for solution for injection, IV (administered by 1 to 2 hours of drip infusion), dose determination : if BSA ≥0.6 m\^2: 2500 IU/m\^2 every 14 days if BSA \<0.6 m\^2: 82.5 IU/kg every 14 days
Study NCT05891665 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticotomy
Description: A corticotomy procedure will be applied with some osteoperforations during the surgical exposure of the impacted canine. Then this will be followed after 8 weeks with another surgical stimulation using piezosurgery.
Study NCT05891665 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional traction of the impacted canine without corticotomy
Description: In this group of patients, the traction of the impacted canine will be performed traditionally without the involvement of additional surgical intervention.
Study NCT01419132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 125-250 mg furosemide bid
Study NCT01419132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Furosemide
Description: 125-250 mf furosemide bid
Study NCT03091504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow nasal cannula is a soft and flexible nasal prongs with adjustable head strap fits over the patient's ears, it delivers a broad variety of gas flows directly into the nares without gas jetting.
Study NCT03091504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate
Description: Albuterol is a short acting inhaled bronchodilator
Study NCT03157700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REAL media curriculum
Description: REAL media is a 5-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth substance use.
Study NCT00909207 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
Study NCT00329056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: Two doses will be compared to placebo: 40 or 80 mg of MitoQ once daily for a period of 12 months.
Study NCT00329056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MitoQ
Description: Two doses will be compared to placebo: 40 or 80 mg of MitoQ once daily for a period of 12 months.
Study NCT01277003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aculife Magnetic Wave Therapist
Description: two therapeutic points, each for 15 minutes
Study NCT04481022 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: proximal control exercises
Description: study investigates the effectiveness of proximal control exercises for patients with PFPS in improving pain and function. The findings of this systematic review are consistent with previous evidence reporting effectiveness of exercise for PFPS. In particular, there is consistent moderate to high quality evidence (three RCT, one CCT, three cohort studies, and one case series) that proximal interventions provide relief of pain and improved function in the short term, whereas the knee programs have variable effectiveness. Physical therapists should consider using proximal interventions for early stage treatment for PFPS (Peters et al., 2013).~After 4 weeks of a combined knee and hip strengthening exercise program, sedentary females with PFPS had a greater reduction in pain during stair descent compared to the group who performed knee strengthening exercises only. Both groups also showed significant improvement in function and pain during stair ascent (Fakuda et al., 2010).
Study NCT01277003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: tow therapeutic points, each for 15 minutes
Study NCT01675089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: The treatment group will receive 15-minute intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
Study NCT02058823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.
Study NCT02058823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: The subjects receive 1 oral pill of Valsartan each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 40 mg.
Study NCT02058823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: The subjects receive 1 oral pill of Amlodipine each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 6,944 mg of amlodipine besilate with 5 mg of amlodipine.
Study NCT01256177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate (SEROQUEL) Extended Release
Description: Quetiapine fumarate extended release(XR) will be administered orally, once daily in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
Study NCT02332707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg capsules taken b.i.d. at a total daily dose of 800-1400 mg based on participant body weight.
Study NCT01256177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching quetiapine extended release(XR) 50 mg, 200 mg, and 300 mg tablets will be orally administered once daily, in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
Study NCT02587611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elemental liquid diet
Description: This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg \[13C\]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
Study NCT02587611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard semi-solid diet
Description: This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg \[13C\]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
Study NCT03928197 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Inbody S10
Description: Bio-electrical impedance measurement every 5 minutes
Study NCT02493569 — intervention group
Intervention type: PROCEDURE
Intervention: The radical mastectomy of breast cancer
Description: The radical mastectomy of breast cancer could be used for the treatment of breast cancer during the observation.
Study NCT01111305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reslizumab
Study NCT03928197 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tape measurements
Description: Every 5 minutes, circumference of every leg is measured using a tape measure
Study NCT01111305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diethylcarbamazine
Study NCT01111305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diethylcarbamazine
Study NCT01111305 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05752929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: correction scheme with Rapid Acting Insulin Analogs according with the Umpierrez sensitive correction scheme
Study NCT05752929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: correction scheme with Rapid Acting Insulin Analogs according with the Davidson correction scheme
Study NCT00962845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: 200 mg twice daily in the first ten patients. If the first ten patients tolerate this dosage schedule (200 mg bid) without significant side effects (Grade 3 or greater gastrointestinal upset, skin toxicity, myopathy or any visual disturbances whatsoever), the second ten patients will be enrolled at a dose of 400 mg bid
Study NCT02789657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80 mg/m2 (or nab-paclitaxel 80-100 mg/m2) weekly
Study NCT03928197 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SOMNOtouchTMNIBP, Vivisol, Belgium
Description: Continous measurement of blood pressure, heart rate and saturation
Study NCT00811213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SleepStyle 200 Auto Series with SensAwake
Description: Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
Study NCT02789657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Either every 3 weeks (8 mg/kg cycle 1 then 6 mg/kg cycles 2-4) or weekly (4 mg/kg week 1 then 2 mg/kg weeks 2-12)
Study NCT02806076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No-touch RFA arm
Description: No-touch RFA arm indicates RFA procedure without direct tumor puncture. In this study, RFA is done by using dual cooled electrode.
Study NCT00811213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SleepStyle 200 Auto Series with out SensAwake
Description: Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
Study NCT02789657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: every 3 weeks (840 mg cycle 1 then 420 mg cycles 2-4) or weeks 1 and 2 cycle 1 (420 mg each dose) during the first 3-6 weeks of treatment, then 420 mg day 1 of cycles 2-4.
Study NCT02789657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 2 administered weekly with no planned treatment breaks
Study NCT02789657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast surgery
Description: breast conserving or mastectomy
Study NCT02789657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC
Description: doxorubicin and cyclophosphamide (AC) every 2 or 3 weeks for 4 cycles~Dose-dense AC: Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 every 2 weeks x 4 cycles~Standard AC: Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 r every 3 weeks x 4 cycles
Study NCT00983567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: teen web
Description: Min web
Study NCT00983567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: teen web
Description: Min web
Study NCT01679002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Study NCT01947062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Cisplatin & etoposide
Description: Patients will receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.
Study NCT01947062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Cisplatin & etoposide along with oral cyclophosphamide
Description: Patients will be treated with oral cyclophosphamide at a daily dose of 50mg. Patients will also receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.
Study NCT02247648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tramadol
Description: Patients from tramadol group received tramadol 100 mg day one, 100 mg day 2, and 200 mg day 3
Study NCT02247648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients from control group received a shame tramadol pill on day one, two, and 3
Study NCT02284425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1193
Study NCT02284425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00473122 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Delayed-Immediate Breast Reconstruction
Description: Immediate reconstruction surgery if no XRT required; or reconstruction surgery delayed until XRT complete.
Study NCT04315584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT Scans
Study NCT04315584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT Scans
Study NCT04315584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiparametric Magnetic Resonance Imaging Scan
Description: Undergo a multiparametric MRI scan
Study NCT01679002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Study NCT01728779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: Commercially available nelfinavir (1250 mg) will be administered orally twice daily for 14 days.
Study NCT01728779 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation (SBRT)
Description: 15 Gy dose (per lesion site) of SBRT will be administered
Study NCT04315584 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: IV (intravenous) administration of radiotracer
Study NCT04315584 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18 fluorodopa
Description: IV (intravenous) administration of radiotracer
Study NCT02086643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retroclavicular block
Description: Retroclavicular ultrasound guided nerve block with total injection of 40 ml of a mixture of 20 ml ropivacaine 0,5% (5 mg/ml) + 20 ml mepivacaine 1,5% (15 mg/ml) + epinephrine 1 : 400 000 (2,5 mcg/ml). Incremental injections of 5 ml separated by an aspiration test.